Ligand Pharmaceuticals (LGND)

• Market cap: $2.04B
• 1 day: -1.36%
• 5 days: 3.71%
• 1 month: 4.49%
• 3 months: -7.40%
• 6 months: 0.05%
• Year to date: 1.33%
• 1 year: 57.19%
• 5 years: 11.45%
• 10 years: 41.50%
• Sector: Healthcare
• Industry: Biotechnology

About: Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Employees: 68

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

527% more call options, than puts

Call options by funds: $3.56M | Put options by funds: $567K

86% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 22

77% more repeat investments, than reductions

Existing positions increased: 106 | Existing positions reduced: 60

8% more capital invested

Capital invested by funds: $1.81B [Q3] → $1.95B (+$146M) [Q4]

6% more funds holding

Funds holding: 239 [Q3] → 253 (+14) [Q4]

2.37% less ownership

Funds ownership: 98.8% [Q3] → 96.43% (-2.37%) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $143 30% upside
• Avg. target: $143 30% upside
• High target: $143 30% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Stifel Annabel Samimy 44% 1-year accuracy 4 / 9 met price target

30% upside $143

Buy Initiated

10 Apr 2025